Correlation Between Univacco Technology and Genovate Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Univacco Technology and Genovate Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Univacco Technology and Genovate Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Univacco Technology and Genovate Biotechnology Co, you can compare the effects of market volatilities on Univacco Technology and Genovate Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Univacco Technology with a short position of Genovate Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Univacco Technology and Genovate Biotechnology.

Diversification Opportunities for Univacco Technology and Genovate Biotechnology

0.02
  Correlation Coefficient

Significant diversification

The 3 months correlation between Univacco and Genovate is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Univacco Technology and Genovate Biotechnology Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genovate Biotechnology and Univacco Technology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Univacco Technology are associated (or correlated) with Genovate Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genovate Biotechnology has no effect on the direction of Univacco Technology i.e., Univacco Technology and Genovate Biotechnology go up and down completely randomly.

Pair Corralation between Univacco Technology and Genovate Biotechnology

Assuming the 90 days trading horizon Univacco Technology is expected to under-perform the Genovate Biotechnology. In addition to that, Univacco Technology is 9.37 times more volatile than Genovate Biotechnology Co. It trades about -0.04 of its total potential returns per unit of risk. Genovate Biotechnology Co is currently generating about -0.21 per unit of volatility. If you would invest  2,235  in Genovate Biotechnology Co on September 2, 2024 and sell it today you would lose (50.00) from holding Genovate Biotechnology Co or give up 2.24% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Univacco Technology  vs.  Genovate Biotechnology Co

 Performance 
       Timeline  
Univacco Technology 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Univacco Technology are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Univacco Technology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Genovate Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Genovate Biotechnology Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Genovate Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Univacco Technology and Genovate Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Univacco Technology and Genovate Biotechnology

The main advantage of trading using opposite Univacco Technology and Genovate Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Univacco Technology position performs unexpectedly, Genovate Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genovate Biotechnology will offset losses from the drop in Genovate Biotechnology's long position.
The idea behind Univacco Technology and Genovate Biotechnology Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years